{"id":68602,"date":"2026-06-27T07:45:48","date_gmt":"2026-06-27T05:45:48","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors\/"},"modified":"2026-06-27T07:45:48","modified_gmt":"2026-06-27T05:45:48","slug":"peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors\/","title":{"rendered":"Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Jun 26. doi: 10.1158\/2326-6066.CIR-25-1611. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Immune checkpoint inhibitors (ICIs) have transformed cancer care, at times generating durable partial or even complete responses in advanced cancers. However, only a minority of patients experience these &#8220;excellent&#8221; responses. Thus, there is a need for novel biomarkers that can identify those with robust clinical benefit. To address this, we prospectively collected blood samples from 124 patients with advanced and\/or metastatic pan-solid tumors treated as standard of care with anti-PD1 or anti-PDL1 alone or in combination with other agents. In this cohort, 30 of 124 (24.2%) patients were classified as excellent responders (ERs), defined as experiencing a complete response or a durable partial response with progression-free survival (PFS) \uf0b3 one year. Peripheral immune cells were analyzed by Cytometry by Time-of-Flight and cytokines were analyzed using a multiplex immunoassay. At baseline and early-on-treatment, ERs had elevated concentrations of Th17-associated cytokines, IL-17F, IL-21, and IL-23, and decreased IL-8 compared to non-ERs (p&lt;0.05). Elevated on-treatment IL-6 was also associated with non-ERs (p&lt;0.05). High baseline IL-17F and IL-23 were associated with superior PFS, and high baseline IL-8 with inferior overall survival (p&lt;0.05). Non-ERs demonstrated decreased proportions of Th17 cells from baseline to early-on-treatment. Regression analysis of functional markers in non-ERs showed a proliferation of exhaustion-like Th17 cells (Ki67+TIGIT+) from baseline to early-on-treatment (p&lt;0.01), which was not present in ERs. This study identifies the Th17 pathway as a potential correlate of excellent ICI response and represents a comprehensive exploration of peripheral immune signatures associated with durable ICI benefit.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42360819\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260627014548&amp;v=2.20.0\">42360819<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1611\">10.1158\/2326-6066.CIR-25-1611<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Jun 26. doi: 10.1158\/2326-6066.CIR-25-1611. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed cancer care, at times generating durable partial or even complete responses in advanced cancers. However, only a minority of patients experience these &#8220;excellent&#8221; responses. Thus, there is a need for novel biomarkers that can identify those &#8230; <a title=\"Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/27\/peripheral-th17-immune-signature-associates-with-excellent-response-to-anti-pd1-anti-pd-l1-therapy-across-solid-tumors\/\" aria-label=\"Read more about Peripheral Th17 immune signature associates with excellent response to anti-PD1\/anti-PD-L1 therapy across solid tumors\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-68602","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=68602"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68602\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=68602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=68602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=68602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}